series-b
Stage
2020
Founded
1
Investors
About
Anaveon is a clinical-stage biopharmaceutical company developing antibody and protein-based biologics to modulate the immune system for autoimmune diseases and oncology. Its lead programs include ANV200, a PD-1–targeting T‑cell depleting antibody for autoimmune indications, and ANV600, in Phase I/II for solid tumours.
Explore Anaveon's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.